We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
+5.38%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
AUM
$72.1M
AUM Growth
-$22.2M
Cap. Flow
-$22.6M
Cap. Flow %
-31.33%
Top 10 Hldgs %
100%
Holding
8
New
Increased
Reduced
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$14.5M
2
KYNB
Kyntra Bio
KYNB
+$8.14M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ACRS icon
1
Aclaris Therapeutics
ACRS
$744M
$35.2M 48.8%
1,954,904
XLRN
2
DELISTED
Acceleron Pharma
XLRN
$18.7M 25.92%
108,630
VRNA
3
DELISTED
Verona Pharma
VRNA
$6.09M 8.44%
1,111,112
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
$5.99M 8.31%
1,641,804
EPZM
5
DELISTED
Epizyme, Inc
EPZM
$5.11M 7.09%
998,278
NVAX icon
6
Novavax
NVAX
$1.21B
$1.04M 1.44%
5,000
KYNB
7
Kyntra Bio
KYNB
$28.3M
-12,231
Closed -$8.14M
NTRA icon
8
Natera
NTRA
$36.1B
-127,305
Closed -$14.5M

Similar funds

Foresite Capital Management III's Q3 2021 Portfolio in Review

As of Q3 2021, Foresite Capital Management III held 8 positions worth $72.1M, down 24% from $94.3M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management III withdrew a net $22.6M in Q3 2021, closing 2 positions. Its most notable exit was Natera, an estimated $14.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Foresite Capital Management III fully exited Natera in Q3 2021, selling an estimated $14.5M.
  • Foresite Capital Management III's ten largest holdings make up 100% of its $72.1M portfolio in Q3 2021.
  • Foresite Capital Management III opened 0 new positions and closed 2 in Q3 2021.
  • Foresite Capital Management III's portfolio value fell 24% quarter-over-quarter to $72.1M.

Based on Foresite Capital Management III's 13F filing for Q3 2021, filed 12 Nov 2021.